PT - JOURNAL ARTICLE AU - Shmueli, Erez AU - Mansuri, Ronen AU - Porcilan, Matan AU - Amir, Tamar AU - Yosha, Lior AU - Yechezkel, Matan AU - Patalon, Tal AU - Handelman-Gotlib, Sharon AU - Gazit, Sivan AU - Yamin, Dan TI - A Multilayer Model for Early Detection of COVID-19 AID - 10.1101/2021.02.25.21252470 DP - 2021 Jan 01 TA - medRxiv PG - 2021.02.25.21252470 4099 - http://medrxiv.org/content/early/2021/03/01/2021.02.25.21252470.short 4100 - http://medrxiv.org/content/early/2021/03/01/2021.02.25.21252470.full AB - Current efforts for COVID-19 screening mainly rely on reported symptoms and potential exposure to infected individuals. Here, we developed a machine-learning model for COVID-19 detection that utilizes four layers of information: 1) sociodemographic characteristics of the tested individual, 2) spatiotemporal patterns of the disease observed near the testing episode, 3) medical condition and general health consumption of the tested individual over the past five years, and 4) information reported by the tested individual during the testing episode. We evaluated our model on 140,682 members of Maccabi Health Services, tested for COVID-19 at least once between February and October 2020. These individuals had 264,516 COVID-19 PCR-tests, out of which 16,512 were found positive. Our multilayer model obtained an area under the curve (AUC) of 81.6% when tested over all individuals, and of 72.8% when tested over individuals who did not report any symptom. Furthermore, considering only information collected before the testing episode – that is, before the individual may had the chance to report on any symptom – our model could reach a considerably high AUC of 79.5%. Namely, most of the value contributed by the testing episode can be gained by earlier information. Our ability to predict early the outcomes of COVID-19 tests is pivotal for breaking transmission chains, and can be utilized for a more efficient testing policy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe research was supported by the Israel Science Foundation (grant No. 3409/19) within the Israel Precision Medicine Partnership program, and the European Research Council (ERC) project \#949850. The funders has no role in the design of the study, collection, analysis, and interpretation of data.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by MHS' Helsinki institutional review board, protocol number 0093-20-MHS, signed on October 21, 2020. Informed consent was waived as identifying details were removed before the analysis.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAccess to the data used for this study can be made available upon request and is subject to internal review approval from the institutional review board of MHS with the current data sharing guidelines of MHS and Israeli law.